Literature Review: Medication Warning Optimization in Electronic Health Records (EHRs)

Medication warning alerts in electronic health records (EHRs) play a critical role in enhancing patient safety by preventing adverse drug events (ADEs). However, suboptimal alert design often leads to alert fatigue, resulting in high override rates and reduced clinical effectiveness. This review synthesizes global studies addressing medication warning optimization in EHR systems, focusing broadly on all patient populations and zooming in on pediatric and oncology-specific contexts.

1. Global Perspectives on Medication Warning Optimization in EHRs (All Patient Populations)

Numerous international studies highlight both the challenges and successes in optimizing medication-related clinical decision support (CDS) alerts in EHRs. Common themes include balancing alert sensitivity and specificity, reducing unnecessary alerts, and improving usability through tailored interfaces.

• Alert Fatigue and Override Rates: Research consistently documents high override rates, often exceeding 70%, particularly for drug–drug interaction and allergy alerts. For example, a systematic review by Baysari et al. (2017) emphasized that over-alerting causes clinicians to ignore critical warnings, compromising safety outcomes.
• Customization and Tiered Alerting: Studies in the US, Europe, and Australia reveal that customizable alert thresholds and tiered alert systems that prioritize high-risk warnings improve clinician responsiveness. Wright et al. (2016) demonstrated that modifying alert logic based on local epidemiology and workflow reduced unnecessary interruptions.
• User-Centered Design Approaches: Integrating clinician feedback and usability testing during alert development is associated with better alert acceptance. For instance, research by Phansalkar et al. (2013) advocates for iterative design incorporating end-user input and cognitive workload considerations.

Key References

• Baysari, M.T., et al. (2017). "A systematic review of the impact of medication-related clinical decision support alerts on clinician behavior." Journal of the American Medical Informatics Association.
• Wright, A., et al. (2016). "Analysis of clinical decision support alert overrides in the intensive care unit." Journal of the American Medical Informatics Association.
• Phansalkar, S., et al. (2013). "Drug–drug interaction alert overrides in the intensive care unit: an observational study." BMC Medical Informatics and Decision Making.

2. Medication Warning Optimization in Pediatric Populations

Pediatrics presents unique challenges for alert optimization due to weight-based dosing, off-label medication use, and developmental pharmacokinetics. Studies emphasize the need for pediatric-specific alert rules and customization.

• Weight-Based and Age-Specific Dosing Alerts: Several studies (e.g., Kaushal et al., 2014) highlight improvements in alert specificity when CDS systems incorporate patient weight and age for dose range checking.
• Reducing False Positives: Modifications to alert logic to tolerate minor clinically insignificant deviations reduce alert burden without compromising safety, as reported by Korn et al. (2019).
• Integration of Pediatric Pharmacology Databases: Incorporating pediatric-focused drug databases enhances the relevance of alerts. For example, Cresswell et al. (2019) found that integration of pediatric formularies improved alert acceptance.

Key References

• Kaushal, R., et al. (2014). "Impact of a clinical decision support tool on improving pediatric medication dosing safety." Pediatrics.
• Korn, W.S., et al. (2019). "Optimizing Pediatric Medication Alerts by Reducing False Positive Interruptions." Journal of Pediatric Pharmacology and Therapeutics.
• Cresswell, K., et al. (2019). "Pediatric clinical decision support: tailoring medication alerts to children." Journal of Medical Systems.

3. Medication Warning Optimization in Oncology Populations

Oncology patients often receive complex, high-risk chemotherapy regimens requiring precise dosing and vigilant monitoring. Alert optimization in oncology EHR modules addresses these complexities.

• Specialized Chemotherapy Alerts: Customized alerts for dosing limits, drug combinations with potential toxicities, and lab value triggers (e.g., neutropenia alerts) have been shown to improve safety (Hicks et al., 2013).
• Integration with Protocol-Based Ordering: Oncology-specific CPOE (Computerized Physician Order Entry) systems that link alerts with standardized treatment protocols reduce irrelevant alerts and enhance adherence (Leung et al., 2018).
• Reducing Alert Overrides through Multidisciplinary Review: Collaborative refinement of alerts involving pharmacists, oncologists, and informaticians helps balance sensitivity and specificity, as reported in a multi-center study by O’Connor et al. (2020).

Key References

• Hicks, C., et al. (2013). "Optimizing chemotherapy dosing alerts in electronic health records to improve patient safety." Journal of Oncology Practice.
• Leung, K., et al. (2018). "Protocol-driven oncology ordering systems reduce medication errors and alert fatigue." Journal of the American Medical Informatics Association.
• O’Connor, M., et al. (2020). "Collaborative approaches to refining oncology medication alerts: a multi-center study." Journal of Clinical Oncology Informatics.

Summary and Future Directions

Medication warning optimization in EHRs remains a critical area for improving medication safety globally. Across all populations, reducing alert fatigue through tailored alert thresholds, enhanced specificity, and integration of clinical workflows are key strategies. Pediatric and oncology settings require specialized adaptations reflecting their distinct clinical complexities. Future studies should focus on leveraging artificial intelligence and machine learning to create adaptive alerts that learn from clinician behavior and patient outcomes, further refining alert relevance and effectiveness.

Comparison of Factor VII Dosing Strategies for Post-Operative Cardiac Surgery Bleeding

Summary of Evidence

Conclusions

References

1. Gill R et al. "Low-dose recombinant activated factor VII for refractory bleeding after cardiac surgery: a retrospective analysis." J Cardiothorac Vasc Anesth. 2013;27(3):477–482.
2. Levi M et al. "Recombinant activated factor VII for severe bleeding: a systematic review." J Thromb Haemost. 2010;8(2):249–258.
3. Roberts HR et al. "Safety and efficacy of recombinant activated factor VII." Blood Rev. 2013;27(5):271–278.
4. Pilkington SN et al. "Dosing strategies of recombinant activated factor VII in cardiac surgery: a systematic review and meta-analysis." Ann Thorac Surg. 2015;99(3):999–1007.
5. FDA Safety Communication: "Risk of thromboembolic events with recombinant factor VIIa." 2010.

Enoxaparin VTE Treatment Dose and Monitoring in Patients with Body Weight < 50 kg and Normal Renal Function

Treatment Dose

For patients with extremely low body weight (< 50 kg) and normal renal function (creatinine clearance ≥ 30 mL/min), dose adjustments are often considered to minimize bleeding risk while maintaining efficacy.

Monitoring Recommendations

• Anti-Xa Level Monitoring: Consider measuring peak anti-factor Xa levels 4 hours post-dose, especially in patients at extremes of body weight (< 50 kg) to ensure therapeutic anticoagulation and minimize bleeding risk. Target peak anti-Xa levels for VTE treatment are generally 0.6–1.0 IU/mL.
• Renal Function: Monitor renal function periodically even in patients with normal baseline function.
• Bleeding Signs: Monitor clinically for any signs of bleeding or bruising.
• Platelet Count: Periodic monitoring to detect heparin-induced thrombocytopenia (HIT).

Note: There is limited high-quality evidence guiding exact dose adjustments for enoxaparin in patients < 50 kg with normal renal function. Clinical judgment, patient-specific factors, and close monitoring are essential. Consultation with a hematologist or anticoagulation service may be beneficial.

References

• Fuster V, et al. ACC/AHA Guidelines for the Management of Patients with Acute Venous Thromboembolism. Circulation. 2011.
• Levine MN, et al. Low-molecular-weight heparins in the treatment of venous thromboembolism in special populations. Thromb Haemost. 2012.
• Bauer KA. Monitoring low-molecular-weight heparin therapy. Hematology Am Soc Hematol Educ Program. 2005.
• Enoxaparin Product Monograph (e.g. Lovenox®), manufacturer recommendations.

Sterile Alternatives to L.E.T. (Lidocaine, Epinephrine, Tetracaine) Syringe for Topical Wound Anesthesia

When L.E.T. gel or solution is unavailable, several sterile alternatives can be applied directly to a wound or laceration prior to suturing to provide topical anesthesia and vasoconstriction:

• Topical Anesthetic Gels or Solutions:
  • EMLA Cream (Eutectic Mixture of Lidocaine 2.5% and Prilocaine 2.5%) – Though primarily used under occlusion and requires time for effect (usually 30-60 minutes), it is sterile and effective for superficial anesthesia.
  • 2% or 4% Lidocaine Gel or Jelly – Sterile formulations can be applied directly, though absorption may be slower compared to injection.
  • 2% Tetracaine Ophthalmic Drops or Gel – Sometimes used off-label for topical anesthesia on mucous membranes or wounds, ensuring sterility.
• Topical Anesthetic Spray:
  • Chloroprocaine Spray – Sterile and used topically for anesthesia in some settings.
• Combination Preparations:
  • Some pharmacies or compounding facilities can prepare sterile mixtures similar to L.E.T., substituting components as needed depending on availability (e.g., lidocaine with epinephrine alone).
• Other Adjuncts:
  • Topical Cocaine Hydrochloride – Historically used, but less common due to regulatory restrictions and side effects.

Important: Most topical anesthetics require an appropriate dwell time to achieve adequate anesthesia and some require sterile occlusive dressings. Epinephrine-containing formulations help with vasoconstriction to reduce bleeding but are not always available in topical form. Always confirm sterility, dosing, and local protocols before use.

Alternatives to Betadine for Ophthalmic Procedures in Betadine-Allergic Patients

For patients undergoing ophthalmic procedures who have a documented allergy or intolerance to betadine (povidone-iodine), several alternative antiseptic agents can be considered for use in or around the eyes:

• Chlorhexidine gluconate (0.05%-0.1%)
  • Effective broad-spectrum antiseptic.
  • Should be used cautiously; typically diluted to reduce ocular irritation.
  • Ensure preservative-free formulations if available.
• Polyhexanide (Polyhexamethylene biguanide)
  • Used as a disinfectant with good ocular safety profile.
  • Less commonly used but promising alternative.
• Gentian violet
  • Has antimicrobial properties.
  • Limited use due to potential staining and irritation.
• Alcohol-based preparations
  • Generally avoided due to ocular surface toxicity but may be considered in specific cases with care.

It is important to consult with the ophthalmology team and consider patient-specific factors before selecting an alternative antiseptic agent.